Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:14 PM
Ignite Modification Date:
2025-12-24 @ 3:14 PM
NCT ID:
NCT00524992
Eligibility Criteria:
* INCLUSION CRITERIA:
* HIV+ adults and children greater than 8 years of age
EXCLUSION CRITERIA:
* Inability or unwillingness to give consent or assent or to comply with study requirements
* Unable to return to NIH or Washington Hospital Center for two follow-up visits over a 9-month period
* New opportunistic or bacterial infection within past 3 months or active opportunistic infection.
* Active malignancy, other than non-melanoma skin cancer and cutaneous Kaposi sarcoma not requiring treatment. Rationale: systemic inflammation may induce microalbuminuria.
* Diabetes by history
* IL-2, IL-7 or IFN-alpha therapy within past 3 months. Rationale: IL-2 and IFN-alpha therapy induce renal dysfunction and IL-7 may be associated with systemic inflammation.
* Non compliance, alcohol use, and drug use are conditions that make study completion unlikely or difficult.
* Diabetes (fasting glucose greater than 125 mg/dL or 2 hour oral glucose tolerance value greater than or equal to 200 mg/dL or current diagnosis of diabetes).
* Serum creatinine greater than 1.4 mg/dL.
* Urine protein/creatinine ratio greater than 0.5 and sustained on at least 2 measurements.
* Pregnant Women
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
8 Years
Study:
NCT00524992
Study Brief:
Protocol Section:
NCT00524992